sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
Company profile
Ticker
SAGE
Exchange
Website
CEO
Jeffrey Jonas
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Sage Securities Corporation • Sage (Bermuda) Ltd. • Sage Therapeutics Limited • Sage Therapeutics GmbH ...
SAGE stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
19 Apr 24
8-K
Regulation FD Disclosure
17 Apr 24
SC TO-I/A
Issuer tender offer statement (amended)
27 Mar 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
SC TO-I/A
Issuer tender offer statement (amended)
21 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
14 Feb 24
S-8
Registration of securities for employees
14 Feb 24
10-K
2023 FY
Annual report
14 Feb 24
8-K
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
14 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
31 Jan 24
Transcripts
SAGE
Earnings call transcript
2023 Q4
14 Feb 24
SAGE
Earnings call transcript
2023 Q3
7 Nov 23
SAGE
Earnings call transcript
2023 Q1
2 May 23
SAGE
Earnings call transcript
2022 Q4
16 Feb 23
SAGE
Earnings call transcript
2022 Q3
8 Nov 22
SAGE
Earnings call transcript
2022 Q2
2 Aug 22
SAGE
Earnings call transcript
2022 Q1
3 May 22
SAGE
Earnings call transcript
2021 Q4
24 Feb 22
SAGE
Earnings call transcript
2021 Q3
2 Nov 21
SAGE
Earnings call transcript
2021 Q2
3 Aug 21
Latest ownership filings
4
Barry E Greene
15 Feb 24
4
Anne Marie Cook
15 Feb 24
4
Laura Gault
15 Feb 24
4
Christopher Benecchi
15 Feb 24
4
KIMI IGUCHI
15 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 148.71 mm | 148.71 mm | 148.71 mm | 148.71 mm | 148.71 mm | 148.71 mm |
Cash burn (monthly) | (no burn) | 4.26 mm | 70.62 mm | 57.64 mm | 45.29 mm | 45.67 mm |
Cash used (since last report) | n/a | 28.96 mm | 480.08 mm | 391.86 mm | 307.89 mm | 310.46 mm |
Cash remaining | n/a | 119.75 mm | -331.37 mm | -243.15 mm | -159.18 mm | -161.75 mm |
Runway (months of cash) | n/a | 28.1 | -4.7 | -4.2 | -3.5 | -3.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 193 |
Opened positions | 31 |
Closed positions | 62 |
Increased positions | 82 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 1.20 tn |
Total shares | 67.70 mm |
Total puts | 258.70 k |
Total calls | 604.90 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 7.70 mm | $158.38 bn |
Wellington Management | 6.57 mm | $135.26 bn |
BIIB Biogen | 6.24 mm | $539.95 mm |
Vanguard | 5.21 mm | $107.18 bn |
RTW Investments | 5.15 mm | $105.98 bn |
STT State Street | 4.38 mm | $90.11 bn |
BLK Blackrock | 4.22 mm | $86.78 bn |
BLVGF Bellevue | 3.51 mm | $72.30 bn |
BBBOF BB Biotech | 3.10 mm | $138.89 mm |
JPM JPMorgan Chase & Co. | 1.67 mm | $34.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Feb 24 | Barry E Greene | Stock Option Common Stock | Grant | Acquire A | No | No | 23.02 | 168,000 | 3.87 mm | 168,000 |
13 Feb 24 | Cook Anne Marie | Common Stock | Grant | Acquire A | No | No | 0 | 11,250 | 0.00 | 25,181 |
13 Feb 24 | Cook Anne Marie | Stock Option Common Stock | Grant | Acquire A | No | No | 23.02 | 22,500 | 517.95 k | 22,500 |
13 Feb 24 | Laura Gault | Common Stock | Grant | Acquire A | No | No | 0 | 11,250 | 0.00 | 11,477 |
13 Feb 24 | Laura Gault | Stock Option Common Stock | Grant | Acquire A | No | No | 23.02 | 22,500 | 517.95 k | 22,500 |
13 Feb 24 | Christopher Benecchi | Common Stock | Grant | Acquire A | No | No | 0 | 13,500 | 0.00 | 19,430 |
13 Feb 24 | Christopher Benecchi | Stock Option Common Stock | Grant | Acquire A | No | No | 23.02 | 27,000 | 621.54 k | 27,000 |
13 Feb 24 | Iguchi Kimi | Common Stock | Grant | Acquire A | No | No | 0 | 11,250 | 0.00 | 81,679 |
13 Feb 24 | Iguchi Kimi | Stock Option Common Stock | Grant | Acquire A | No | No | 23.02 | 22,500 | 517.95 k | 22,500 |
News
Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $19
18 Apr 24
Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $17
18 Apr 24
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
18 Apr 24
TD Cowen Maintains Buy on Sage Therapeutics, Lowers Price Target to $16
18 Apr 24
Needham Reiterates Hold on Sage Therapeutics
18 Apr 24
Press releases
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
17 Apr 24
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
11 Apr 24
Sage Therapeutics to Present at Upcoming March Investor Conferences
28 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
14 Feb 24
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
31 Jan 24